Evaluation of a Nanoemulsion Formulation Strategy for Oral Bioavailability Enhancement of Danazol in Rats and Dogs

Harikrishna Devalapally; Svitlana Silchenko; Feng Zhou; Jessica McDade; Galina Goloverda; Albert J. Owen; Ismael J. Hidalgo

doi:10.1002/jps.23667

Evaluation of a Nanoemulsion Formulation Strategy for Oral Bioavailability Enhancement of Danazol in Rats and Dogs

Harikrishna Devalapally, Svitlana Silchenko, Feng Zhou, Jessica McDade, Galina Goloverda, Albert J. Owen, Ismael J. Hidalgo

In: Journal of Pharmaceutical Sciences · 2013 · vol. 102(10) , pp. 3808–3815 · doi:10.1002/jps.23667 · PMID:23878097 · W2096485633

article OA: closed CC0 ⤵ 3 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Researchers developed a nanoemulsion formulation to enhance the oral bioavailability of danazol and tested its effectiveness in rats and dogs.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (35)

Bioavailability of danazol-hydroxypropyl-β-cylodextrin complex by different routes of administration via openalex
Characterization and bioavailability of danazol-hydroxypropyl β-cyclodextrin coprecipitates via openalex
Evaluation of the Impact of Surfactant Digestion on the Bioavailability of Danazol after Oral Administration of Lipidic Self-Emulsifying Formulations to Dogs via openalex
Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs via openalex
Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis via openalex
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex
Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules via openalex
Surface treatment of the hydrophobic drug danazol to improve drug dissolution via openalex
Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation via openalex
doi:10.1016/s0928-0987(00)00167-6 via openalex
doi:10.1166/jnn.2006.440 via openalex
doi:10.1016/s0168-3659(99)00094-2 via openalex
doi:10.1016/j.ejps.2006.04.016 via openalex
doi:10.1021/jm800002y via openalex
doi:10.1038/mt.2009.91 via openalex
doi:10.1002/jps.22157 via openalex
doi:10.2174/156720105774370267 via openalex
doi:10.1016/j.ijpharm.2007.06.016 via openalex
doi:10.1002/jps.10511 via openalex
doi:10.1039/b912460h via openalex
doi:10.1016/j.ijpharm.2008.08.046 via openalex
doi:10.1002/jps.23170 via openalex
doi:10.1023/b:pham.0000016235.32639.23 via openalex
doi:10.1002/jps.1023 via openalex
doi:10.1002/jps.21451 via openalex
doi:10.1021/mp300164u via openalex
doi:10.1016/j.ijpharm.2004.08.024 via openalex
doi:10.1023/a:1016268311867 via openalex
doi:10.1002/jps.21650 via openalex
doi:10.1002/jps.21425 via openalex
doi:10.1002/jps.2600760404 via openalex
doi:10.1016/0378-5173(82)90038-2 via openalex
doi:10.1016/j.ejpb.2008.09.003 via openalex
doi:10.1016/j.ijpharm.2009.03.008 via openalex
doi:10.1002/jps.2600830425 via openalex

Cited by (3)

Source provenance

openalex: last seen: 2026-05-11T05:39:31.692385+00:00

License: CC0 · commercial use OK

[1] Bioavailability of danazol-hydroxypropyl-β-cylodextrin complex by different routes of administration via openalex

[2] Characterization and bioavailability of danazol-hydroxypropyl β-cyclodextrin coprecipitates via openalex

[3] Evaluation of the Impact of Surfactant Digestion on the Bioavailability of Danazol after Oral Administration of Lipidic Self-Emulsifying Formulations to Dogs via openalex

[4] Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs via openalex

[5] Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis via openalex

[6] Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex

[7] Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules via openalex

[8] Surface treatment of the hydrophobic drug danazol to improve drug dissolution via openalex

[9] Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion Formulation via openalex

[10] doi:10.1016/s0928-0987(00)00167-6 via openalex

[11] doi:10.1166/jnn.2006.440 via openalex

[12] doi:10.1016/s0168-3659(99)00094-2 via openalex

[13] doi:10.1016/j.ejps.2006.04.016 via openalex

[14] doi:10.1021/jm800002y via openalex

[15] doi:10.1038/mt.2009.91 via openalex

[16] doi:10.1002/jps.22157 via openalex

[17] doi:10.2174/156720105774370267 via openalex

[18] doi:10.1016/j.ijpharm.2007.06.016 via openalex

[19] doi:10.1002/jps.10511 via openalex

[20] doi:10.1039/b912460h via openalex

[21] doi:10.1016/j.ijpharm.2008.08.046 via openalex

[22] doi:10.1002/jps.23170 via openalex

[23] doi:10.1023/b:pham.0000016235.32639.23 via openalex

[24] doi:10.1002/jps.1023 via openalex

[25] doi:10.1002/jps.21451 via openalex

[26] doi:10.1021/mp300164u via openalex

[27] doi:10.1016/j.ijpharm.2004.08.024 via openalex

[28] doi:10.1023/a:1016268311867 via openalex

[29] doi:10.1002/jps.21650 via openalex

[30] doi:10.1002/jps.21425 via openalex

[31] doi:10.1002/jps.2600760404 via openalex

[32] doi:10.1016/0378-5173(82)90038-2 via openalex

[33] doi:10.1016/j.ejpb.2008.09.003 via openalex

[34] doi:10.1016/j.ijpharm.2009.03.008 via openalex

[35] doi:10.1002/jps.2600830425 via openalex